Schedule I

The controlled substances listed in this Code section are included in Schedule I: (1) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, pursuant to this article, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (A) Acetylmethadol; (B) Allylprodine; (C) Reserved; (D) Alphameprodine; (E) Alphamethadol; (F) Benzethidine; (G) Betacetylmethadol; (H) Betameprodine; (I) Betamethadol; (J) Betaprodine; (K) Brorphine; (L) Dextromoramide; (M) Dextromorphan; (N) Diampromide; (O) Diethylthiambutene; (P) Dimenoxadol; (Q) Dimetheptanol; (R) Dimethylthiambutene; (S) Dioxaphetyl butyrate; (T) Dipipanone; (U) Ethylmethylthiambutene; (V) Reserved; 250 16-13-25 (W) Etoxeridene; (X) Furethidine; (Y) Hydroxypethidine; (Z) Ketobemidone; (AA) Levomoramide; (BB) Levophenacylmorphan; (CC) Morpheridine; (DD) Noracymethadol; (EE) Norlevorphanol; (FF) Normethadone; (GG) Norpipanone; (HH) Phenadoxone; (II) Phenampromide; (JJ) Phenomorphan; (KK) Phenoperidine; (LL) Piritramide; (MM) Proheptazine; (NN) Properidine; (OO) Propiram; (PP) Racemoramide; (QQ) Trimeperidine; (RR) 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl] benzamide (AH-7921); (SS) 3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide (U-47700); (TT) Methyl-AP-237; (UU) Tianeptine; (2) Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Acetorphine; 251 16-13-25 (B) Acetyldihydrocodeine; (C) Benzylmorphine; (D) Codeine methylbromide; (E) Codeine-N-Oxide; (F) Cyprenorphine; (G) Desomorphine; (H) Dihydromorphine; (I) Etorphine; (J) Heroin; (K) Hydromorphinol; (L) Methyldesorphine; (M) Methyldihydromorphine; (N) Morphine methylbromide; (O) Morphine methylsulfonate; (P) Morphine-N-Oxide; (Q) Myrophine; (R) Nicocodeine; (S) Nicomorphine; (T) Normorphine; (U) Pholcodine; (V) Thebacon; (3) Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) 3, 4-methylenedioxyamphetamine; (B) 5-methoxy-3, 4-methylenedioxyamphetamine; (C) 3, 4, 5-trimethoxyamphetamine; (D) Bufotenine; (E) Diethyltryptamine; 252 16-13-25 (F) Dimethyltryptamine; (G) 4-methyl-2, 5-dimethoxyamphetamine; (H) Ibogaine; (I) Lysergic acid diethylamide; (J) Mescaline; (K) Peyote; (L) N-ethyl-3-piperidyl benzilate; (M) N-methyl-3-piperidyl benzilate; (N) Psilocybin; (O) Psilocyn (Psilocin); (P) Tetrahydrocannabinol, tetrahydrocannabinolic acid, or a combination of tetrahydrocannabinol and tetrahydrocannabinolic acid which does not contain plant material exhibiting the external morphological features of the plant of the genus Cannabis, but not including such substance when found in hemp or hemp products as such terms are defined in Code Section 2-23-3. Tetrahydrocannabinols do not include products approved by the federal Food and Drug Administration under Section 505 of the federal Food, Drug, and Cosmetic Act; (Q) 2, 5-dimethoxyamphetamine; (R) 4-bromo-2, 5-dimethoxyamphetamine; (S) 4-methoxyamphetamine; (T) Cyanoethylamphetamine; (U) (1-phenylcyclohexyl) ethylamine; (V) 1-(1-phenylcyclohexyl) pyrrolidine; (W) Phencyclidine; (X) 1-piperidinocyclohexanecarbonitrile; (Y) 1-phenyl-2-propanone (phenylacetone); (Z) 3, 4-Methylenedioxymethamphetamine (MDMA); (AA) 1-methyl-4-phenyl-4-propionoxypiperidine; (BB) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine; (CC) Reserved; (DD) N-ethyl-3, 4-methylenedioxyamphetamine; 253 16-13-25 (EE) Reserved; (FF) 2,5-Dimethoxy-4-Ethylamphetamine; (GG) Cathinone; (HH) Reserved; (II) PEPAP (1-(2-phenethyl)-4 phenyl-4-acetoxypiperide); (JJ) Reserved; (KK) Para-methoxymethamphetamine (PMMA); (LL) 4,4’-dimethylaminorex; (MM) Reserved; (NN) Reserved; (OO) 3,4-Methylenedioxy-N-Ethylamphetamine; (PP) 4-Methylaminorex; (QQ) N-Hydroxy-3,4-Methylenedioxyamphetamine; (RR) Reserved; (SS) Chlorophenylpiperazine (CPP); (TT) N, N-Dimethylamphetamine; (UU) 1-(1-(2-thienyl)cyclohexy)pyrrolidine; (VV) 4-Bromo-2,5-Dimethoxyphenethylamine (DMPE); (WW) Alpha-Ethyltryptamine; (XX) Methcathinone; (YY) Aminorex; (ZZ) 4-iodo-2,5-dimethoxyamphetamine; (AAA) 4-chloro-2,5-dimethoxyamphetamine; (BBB) 3,4-Methylenedioxypyrovalerone (MDPV); (CCC) 4-Methylmethcathinone (Mephedrone); (DDD) 3,4-Methylenedioxymethcathinone (Methylone); (EEE) 4-Methoxymethcathinone; (FFF) Fluoromethcathinone; (GGG) Fluorophenylpiperazine (FPP); (HHH) 4-iodo-2,5-dimethoxyphenethylamine (2C-I); (III) 4-chloro-2,5-dimethoxyphenethylamine (2C-C); 254 16-13-25 (JJJ) 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]benzeneethanamine (25I-NBOMe); (KKK) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]benzeneethanamine (25C-NBOMe); (LLL) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]benzeneethanamine (25B-NBOMe); (MMM) N,N-Diallyl-5-Methoxytryptamine (5-MeO-DALT); (NNN) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E); (OOO) 2-(2,5-Dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl) ethanamine (25N-NBOMe); (PPP) 4-acetoxy-N-ethyl-N-methyltryptamine (4-AcO-MET); (QQQ) 4-nitro-2,5-dimethoxyphenethylamine (2C-N); (RRR) 5-methoxy-N,N-methylisopropyltryptamine MIPT); (5-MeO- (SSS) Methoxetamine; (TTT) N-acetyl-3,4-methylenedioxymethcathinone; (UUU) 3-(1,3-benzenodioxol-5-yl)-N,2-dimethylpropan-1-amine methylenedioxymethamphetamine methyl homolog); (3,4- (VVV) (2-aminopropyl)-2,3-dihydrobenzofuran (APDB); (WWW) 4-methyl-2,5-dimethoxy-N-[(2-methoxyphenyl) (WWW) methyl]-benzeneethanamine (25D-NBOMe); (XXX) 2-chloro-4,5-methylenedioxymethamphetamine; (YYY) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); (ZZZ) 2-bromo-4,5-methylenedioxymethamphetamine; (AAAA) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25H-NBOMe); (BBBB) Methoxyphencyclidine (MeO-PCP); (CCCC) 4-hydroxy-N-methyl-N-isopropyltryptamine MiPT); (4-OH- (DDDD) N,a-dimethyl-5-benzofuranethanamine (5-MAPB); (EEEE) 1-(1-benzofuran-6-yl)propan-2-amine (6-APB); (FFFF) 1-(1-benzofuran-5-yl)-N-ethylpropan-2-amine EAPB); 255 (5- 16-13-25 (GGGG) Fluorophenmetrazine; (HHHH) 5-methoxy-N,N-Dibutyltryptamine (5-MeO-DBT); (IIII) 5-methoxy-N,N-Diisobutyltryptamine (5-MeO-DIBT); (JJJJ) N-(1,4-dimethylpentyl)-3,4-dimethoxyamphetamine; (KKKK) 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1phenylpropan-2-ol (Zipeprol); (4) Any material, compound, mixture, or preparation which contains any of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Amineptine; (B) Fenethylline; (C) Mesocarb; (D) Methiopropamine; (E) Para-methoxyphenylpiperazine (MeOPP); (5) Any material, compound, mixture, or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers, unless specifically excepted, whenever the existence of these substances, their salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Gamma hydroxybutyric acid (gamma hydroxy butyrate); provided, however, that this does not include any amount naturally and normally occurring in the human body; and (B) Sodium oxybate, when the FDA approved form of this drug is not: (i) In a container labeled in compliance with subsection (a) or (b) of Code Section 26-3-8; and (ii) In the possession of: (I) A registrant permitted to dispense the drug; (II) Any person other than to whom the drug was prescribed; or (III) Any person who attempts to or does unlawfully possess, sell, distribute, or give this drug to any other person; 256 16-13-25 (6) Notwithstanding the fact that Schedule I substances have no currently accepted medical use, the General Assembly recognizes certain of these substances which are currently accepted for certain limited medical uses in treatment in the United States but have a high potential for abuse. Accordingly, unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of methaqualone, including its salts, isomers, optical isomers, salts of their isomers, and salts of these optical isomers, is included in Schedule I; (7) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7); (8) 1-(3-Trifluoromethylphenyl) Piperazine (TFMPP); (9) N-Benzylpiperazine (BZP); (10) 5-Methoxy-N,N-Diisopropyltryptamine (5-MeO-DIPT); (11) Alpha-Methyltryptamine (AMT); (12) Any of the following compounds, derivatives, their salts, isomers, or salts of isomers, halogen analogues, or homologues, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers, halogen analogues, or homologues is possible within the specific chemical designation: (A) Naphthoylindoles; (B) Naphthylmethylindoles; (C) Naphthoylpyrroles; (D) Naphthylideneindenes; (E) Phenylacetylindoles; (F) Cyclohexylphenols; (G) Benzoylindoles; (H) Tricyclic benzopyrans; (I) Adamantoylindoles; (J) Indazole amides; (K) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2, 3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN 55,212-2); (L) Any compound, unless specifically excepted or listed in this or another schedule, structurally derived from 2-aminopropan-1257 16-13-25 one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways: (i) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substitutions, whether or not further substituted in the ring system; (ii) By substitution at the 3-position with an alkyl, alkoxy, or cyclic substitution; (iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, cyclohexyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure; (M) Indole carboxamides; (N) Indole carboxylates; (O) [1,1'-biphenyl]-3-yl-carbamic (URB602); acid, cyclohexyl ester (P) Indazole carboxylates; (Q) [3-(3-carbamoylphenyl)phenyl] (URB597); N-cyclohexylcarbamate (R) 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one (URB754); (S) Indole tetramethylcyclopropanecarbonyls; (T) Napthoylbenzimidazoles; (U) 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone (CB-13); (V) Naphthoylindazoles; (W) Azaindole carboxamide; (13) The fentanyl analog structural class, including any of the following derivatives, their salts, isomers, or salts of isomers, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from fentanyl, and whether or not further modified in any of the following ways: 258 16-13-25 (A) Substitution anywhere on the phenethyl group with: (i) Alkyl group; (ii) Hydroxyl group; (iii) Halide group; (B) Replacement of the phenethyl group with: (i) Thienyl ethyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (ii) Oxotetrazol ethyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (iii) Alkyl group; (iv) Thienyl methyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (v) Benzyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (vi) Furanyl ethyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (vii) Phenyl alkyl group, which can be further substituted with: 259 16-13-25 (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (viii) Pyridinyl ethyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (ix) Diazole ethyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (IV) Nitro group; (x) Thiazole ethyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (xi) Benzoxazolinone ethyl group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (C) Substitution anywhere on the piperidine ring with: (i) Alkyl group; (ii) Allyl group; (iii) Phenyl group; (iv) Ester group; (v) Ether group; (vi) Pyridine group, which can be further substituted with: (I) Alkyl group; 260 16-13-25 (II) Hydroxyl group; (III) Halide group; (vii) Thiazole group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (viii) Oxadiazole group, which can be further substituted with: (I) Alkyl group; (II) Hydroxyl group; (III) Halide group; (IV) Ether group; (D) Substitution anywhere on the propanamide group with: (i) Cyclic alkyl group; (ii) Acyclic alkyl group: (iii) Methoxy group; (E) Replacement of the propanamide group with: (i) Acryloyl amino group; (ii) Acetamide group, which itself can be further substituted with: (I) Cyclic alkyl group; (II) Tetrahydrofuran group; (iii) Methoxy acetamide group; (iv) Furanyl amide group; (v) Amine; (F) Substitution anywhere on the phenyl ring with: (i) Halide group; (ii) Methoxy group; (iii) Alkyl group; (G) Replacement of the phenyl ring with the pyrazine ring; (14) The piperidinyl-sulfonamide structural class, including any of the following compounds, derivatives, their salts, isomers, or salts 261 16-13-25 of isomers, halogen analogues, or homologues, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers, halogen analogues, or homologues is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from piperidinyl-sulfonamide, and whether or not further modified in any of the following ways: (A) By substitution at the 1-position of the piperidinyl ring with any of the following: (i) Alkyl group; (ii) Phenyl alkyl group; (iii) Amino substituted phenyl alkyl group; (iv) Nitro substituted phenyl alkyl group; (v) Cycloalkyl group; (vi) Alkenyl substituent group; (B) By substitution at the 3-position or 4-position of the piperidinyl ring with any of the following: (i) Halide group; (ii) Alkyl group; (iii) Alkoxy substituent; (C) By substitution on the sulfonamide with any of the following: (i) Pyridyl group; (ii) Alkyl group; (iii) Phenyl group; (iv) Phenyl alkyl group; (v) Alkoxy substituted phenyl group; (vi) Halogen substituted phenyl group; (vii) Nitro substituted phenyl group; (viii) Amino substituted phenyl group; (ix) Alkanoylamino substituted phenyl group; (x) Amido substituted phenyl group; 262 16-13-25 (15) The 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45) structural class, including any of the following derivatives, their salts, isomers, or salts of isomers, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from 1-cyclohexyl-4-(1,2- diphenylethyl)-piperazine (MT-45), and whether or not further modified in any of the following ways: (A) Replacement of the cyclohexyl group with any of the following: (i) Cycloheptyl group; (ii) Cyclooctyl group; (B) Substitution on the diphenyl groups with any of the following: (i) Hydroxyl group; (ii) Halide; (iii) Alkoxy group; (iv) Alkyl group; (v) Ester group; (vi) Phenyl ether group; (16) The N-substituted benzimidazole structural class, including any of the following derivatives, their salts, isomers, or salts of isomers unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from N-substituted benzimidazole by substitution at the 1-position with an ethylamine group and by substitution at the 2-position with a benzyl group, whether or not the compound is further modified in any of the following ways: (A) By monoalkyl or dialkyl substitution on the nitrogen of the 1-position ethylamine group, or by inclusion of the nitrogen in a cyclic structure; 263 16-13-25 (B) By substitution on the benzylic carbon of the 2-position benzyl group by alkyl or carboxamide groups; (C) By substitution at the 3-position or 4-position of the benzyl group, or both, with alkyl, hydroxyl, alkoxy, acetoxy, halide, or sulfide groups; (D) By replacement of the 2-position benzyl group with an ethylbenzyl, thiophenol, or methoxybenzene group, which may be further substituted with alkyl, hydroxyl, alkoxy, acetoxy, halide, or sulfide groups; and (E) By substitution at the 5-position or 6-position with a nitro group or primary amine; (17) Clonazolam; (18) Cumyl-pegaclone; (19) Diclazepam; (20) Etizolam; (21) Flualprazolam; (22) Flubromazolam. History. Code 1933, § 79A-806, enacted by Ga. L. 1974, p. 221, § 1; Ga. L. 1978, p. 1668, § 6; Ga. L. 1979, p. 859, § 5; Ga. L. 1980, p. 1746, § 4; Ga. L. 1981, p. 557, § 3; Ga. L. 1982, p. 2403, §§ 11, 16; Ga. L. 1984, p. 22, § 16; Ga. L. 1984, p. 1019, § 1; Ga. L. 1985, p. 1219, § 2; Ga. L. 1986, p. 1555, § 3; Ga. L. 1987, p. 261, § 1; Ga. L. 1989, p. 233, § 1; Ga. L. 1990, p. 8, § 16; Ga. L. 1990, p. 640, § 1; Ga. L. 1992, p. 1131, § 1; Ga. L. 1994, p. 169, §§ 1–3, 3.1; Ga. L. 1996, p. 356, § 1; Ga. L. 2001, p. 816, § 1; Ga. L. 2002, p. 415, § 16; Ga. L. 2003, p. 349, § 2; Ga. L. 2005, p. 1028, § 1/SB 89; Ga. L. 2006, p. 219, § 14/HB 1054; Ga. L. 2008, p. 169, §§ 1, 2/HB 1090; Ga. L. 2010, p. 338, § 1/HB 1309; Ga. L. 2010, p. 860, § 1/SB 353; Ga. L. 2011, p. 656, §§ 1, 2/SB 93; Ga. L. 2012, p. 40, §§ 2, 3/SB 370; Ga. L. 2013, p. 5, § 1/HB 57; Ga. L. 2013, p. 71, §§ 1, 1.1/HB 302; Ga. L. 2013, p. 141, § 16/HB 79; Ga. L. 2014, p. 217, §§ 1-3/HB 835; Ga. L. 2015, p. 883, §§ 1, 2/HB 211; Ga. L. 2016, p. 798, §§ 2, 3/HB 783; Ga. L. 2017, p. 14, §§ 1-4/HB 231; Ga. L. 2017, p. 417, §§ 7-1, 7-2/SB 104; Ga. L. 2018, p. 314, §§ 1-4/HB 830; Ga. L. 2018, p. 1112, § 16/SB 365; Ga. L. 2019, p. 820, § 1/HB 483; Ga. L. 2019, p. 1030, § 3/HB 213; Ga. L. 2021, p. 184, § 26/SB 195; Ga. L. 2021, p. 386, §§ 1-4/HB 367; Ga. L. 2022, p. 803, §§ 1–5/HB 963; Ga. L. 2023, p. 137, §§ 1, 2/HB 332, effective May 1, 2023; Ga. L. 2024, p. 161, §§ 1–3/HB 1326, effective April 22, 2024. Amendments. The 2022 amendment, effective May 13, 2022, substituted “Brorphine” for “Reserved” in subparagraph (1)(K); added subparagraph (1)(UU); substituted “Paramethoxymethamphetamine (PMMA)” for “Reserved” in subparagraph (3)(KK); substituted “4,4’-dimethylaminorex” for “Reserved” in subparagraph (3)(LL); substituted “Methiopropamine” for “Reserved” in subparagraph (4)(C); substituted “an alkyl, alkoxy, or cyclic substitution;” for “a cyclic or acyclic alkyl, substitution or alkoxy; or” at the end of division (12)(L)(ii); and added division (13)(E)(v). The 2023 amendment, effective May 1, 2023, added subparagraph (3)(KKKK), added subparagraph (4)(A), redesignated former subparagraph (4)(A) as subparagraph (4)(B), which formerly read: “Reserved;”, added subpargraph (4)(C), and redesignated former subparagraphs (4)(C) 264 and (4)(D) as present subparagraphs (4)(D) and (4)(E), respectively. The 2024 amendment, effective April 22, 2024, inserted “cyclohexl,” in division (12)(L)(iii); substituted a semicolon for a period at the end of subparagraph (16)(E); and added paragraphs (17) through (22).